Hypertonic saline nebules for patients with cystic fibrosis and bronchioectasis: a review of the clinical and cost-effectiveness
Brown A, Skidmore B
Record ID 32011001289
English
Authors' recommendations:
A systematic review for CF concluded that HS improves mucociliary clearance in short-term clinical trials and appears to increase lung function compared to placebo. It also concluded that HS may be less effective than rhDNase at improving lungfunction after three months, and is equally efficacious and well tolerated compared to mannitol in improving bronchial mucus clearance in patients with CF. Another RCT identified compared rhDNase and HS for children with CF, and found HS was not as effective as daily rhDNase, although there was some variation in individual response. A cost-effectiveness study in a UK context concluded that both alternate-day rhDNase and daily rhDNase are cost-effective relative to HS. However, there was no comparison to placebo in this economic evaluation. With regard to the treatment of BE with HS, the one included trial found HS to be to be a safe, effective, and easily administered adjunct to physiotherapy in select patients.
Details
Project Status:
Completed
Year Published:
2009
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Administration, Inhalation
- Bronchiectasis
- Saline Solution, Hypertonic
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.